10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).
AGM Trading Update
10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).
31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
A recording of the webcast can be accessed via the following link:
https://webcasting.buchanan.uk.com/broadcast/5f154afa4c167c1215797e02
The presentation can be accessed by clicking here.
Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment
29 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and ultimately blindness.
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
Meaningful clinical effect observed in patients out to 12 months post-treatment
Expansion of ongoing Phase 2a study includes plans to open a UK clinical site
24 February 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce positive long-term data from the ongoing Phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and plans to expand the ongoing study. RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and blindness.
“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa
02 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce new positive data in the Company’s ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.
14 June 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the ‘Breakthrough of the Year’ award at last night’s 2019 European Mediscience Awards in London.
8 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces a year-end business update ahead of its preliminary results for the year ended 31 March 2019, which will be announced on Thursday 11 July 2019.